GPRC5D-Related Oral Adverse Events in Multiple Myeloma

EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

EP: 2.Overview of Relapsed/Refractory Multiple Myeloma

EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM

EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

Now Viewing

EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma

EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities

EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management

EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma

This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

Oral toxicities with talquetamab are nearly universal, with taste changes in 72% of patients, dry mouth in 40%, and dysphagia in 25% arising within the first month but persisting long term. Usmani observes these issues with all talquetamab-treated patients, but they are disproportionately severe in African American patients. Nutrition and supportive measures start early, with schedule modifications offering the best toxicity mitigation after patients respond. Rodriguez notes taste changes in more than 90% of patients, predominantly loss of savoriness although sometimes complete ageusia. Capturing severity is challenged by coarse grading criteria when even grade 1 changes impact quality of life and appetite. The pathophysiologic mechanism, be it taste bud disruption or salivary changes, remains unclear, complicating symptomatic management.

Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.